US Patent 8,124,630: Sorafenib Method-of-Treatment Claims, Expiration, Litigation and Patent Landscape

US Patent 8,124,630 protects methods of using sorafenib, particularly sorafenib tosylate, to treat specified carcinomas, myeloid leukemia and villous colon adenoma. The patent does not claim sorafenib as a chemical compound, a tablet formulation, a dosing regimen, a manufacturing process or a biomarker-defined patient population. Its commercial value therefore depends on whether a competing product is indicated, labeled or marketed for one of the claimed diseases before the relevant patent rights expire.

The claims cover:

Lung, pancreatic, thyroid, bladder and colon carcinomas.
Myeloid leukemia.
Villous colon adenoma.
Sorafenib in free-base or pharmaceutically acceptable salt form.
Sorafenib tosylate specifically.

Sorafenib is marketed by Bayer and Onyx Pharmaceuticals as Nexavar. The active ingredient is sorafenib tosylate, also known as BAY 43-9006 tosylate. The FDA approved Nexavar for unresectable hepatocellular carcinoma, advanced renal cell carcinoma and radioactive iodine-resistant differentiated thyroid cancer, with later labeling changes and indication-specific regulatory developments.[1]

What drug and active ingredient does US Patent 8,124,630 cover?

The patent covers sorafenib, chemically identified as N-methyl-2-[[4-[3-[4-chloro-3-(trifluoromethyl)phenyl]ureido]phenoxy]pyridine-2-carboxamide], generally administered as sorafenib tosylate.

Item	Description
Generic name	Sorafenib
Salt used commercially	Sorafenib tosylate
Brand	Nexavar
Development code	BAY 43-9006
Drug class	Multikinase inhibitor
Principal targets	RAF kinases, VEGFR and PDGFR pathways
Patent at issue	US 8,124,630
Patent type	Method of treatment
Primary assignee	Bayer-related patent interests
Commercial product	Nexavar tablets

The claim language contains two related chemical descriptions: “2-carbamoyl-4-pyridyloxy” and “2-(N-methylcarbamoyl)-4-pyridyloxy.” The latter identifies sorafenib. The claim formulas and the patent specification would control construction if the naming discrepancy became relevant in litigation. The discrepancy creates a potential claim-interpretation issue, but it does not appear to expand the claims to an unrelated kinase inhibitor.

What does US Patent 8,124,630 claim?

The patent has 16 claims. Claims 1 through 7 concern sorafenib or a pharmaceutically acceptable salt. Claims 8 through 14 separately recite sorafenib tosylate. Claims 15 and 16 address villous colon adenoma.

Claim coverage by disease and chemical form

Claims	Chemical form	Disease scope	Patient limitation
1	Sorafenib or pharmaceutically acceptable salt	Lung, pancreas, thyroid, bladder or colon carcinoma	Human or animal
2	Sorafenib or pharmaceutically acceptable salt	Myeloid leukemia	Human
3	Depends on claim 1	Lung carcinoma	Human
4	Depends on claim 1	Pancreatic carcinoma	Human
5	Depends on claim 1	Thyroid carcinoma	Human
6	Depends on claim 1	Bladder carcinoma	Human
7	Depends on claim 1	Colon carcinoma	Human
8	Sorafenib tosylate	Lung, pancreas, thyroid, bladder or colon carcinoma	Human or animal
9	Sorafenib tosylate	Myeloid leukemia	Human
10	Depends on claim 8	Lung carcinoma	Human
11	Depends on claim 8	Pancreatic carcinoma	Human
12	Depends on claim 8	Thyroid carcinoma	Human
13	Depends on claim 8	Bladder carcinoma	Human
14	Depends on claim 8	Colon carcinoma	Human
15	Sorafenib or pharmaceutically acceptable salt	Villous colon adenoma	No express human or animal limitation
16	Sorafenib tosylate	Villous colon adenoma	No express human or animal limitation

How broad are the independent claims?

Claims 1, 2, 8, 9, 15 and 16 are the commercially important claims.

Claim 1 is broad in chemical-form terms because it covers sorafenib and pharmaceutically acceptable salts. It is narrower in disease terms because it is limited to five carcinoma categories. It also requires administration of an effective amount.

Claim 2 separately covers myeloid leukemia. This claim is narrower than claim 1 in patient scope because it is limited to humans, but it covers a distinct disease category.

Claim 8 is materially narrower than claim 1 because it is limited to sorafenib tosylate. That limitation aligns the claim closely with Nexavar’s marketed active pharmaceutical ingredient.

Claim 9 applies the tosylate limitation to myeloid leukemia.

Claims 15 and 16 cover villous colon adenoma. Unlike claims 1, 2, 8 and 9, the text supplied for claims 15 and 16 does not expressly limit treatment to a human or animal in need. That omission may affect interpretation and validity analysis, although the specification, prosecution history and enablement record would remain relevant.

What limitations are absent from the claims?

The claims do not expressly require:

A particular dose.
A dosing interval.
Oral administration.
Tablet administration.
A specific treatment duration.
Monotherapy.
Combination therapy.
Prior treatment failure.
A specific tumor stage.
A molecular biomarker.
A mutation in BRAF, RAS, RET or another pathway.
A particular level of kinase inhibition.
A particular pharmaceutical formulation.
A particular manufacturing process.
A specific clinical response.

The “administering an effective amount” limitation is functional. It requires an amount effective for the claimed treatment, but it does not specify a numerical dose. A generic applicant could therefore face infringement risk even if its label omits a precise regimen, if the label instructs treatment of a claimed disease with sorafenib or sorafenib tosylate.

What is the relationship between claims 1 through 7 and claims 8 through 14?

Claims 1 through 7 cover sorafenib broadly, including pharmaceutically acceptable salts. Claims 8 through 14 isolate the tosylate salt.

This creates overlapping protection:

Sorafenib tosylate administered for lung carcinoma may fall within claim 1 and claim 8.
Sorafenib tosylate administered for myeloid leukemia may fall within claim 2 and claim 9.
A specific human lung-cancer treatment may fall within claims 1, 3, 8 and 10.
A specific human thyroid-cancer treatment may fall within claims 1, 5, 8 and 12.

The dependent claims add disease specificity but do not introduce dose, formulation or patient-selection restrictions. Their practical role is to provide fallback positions if a court narrows or invalidates the broader disease-group claims.

When does US Patent 8,124,630 lose exclusivity?

The patent’s enforceable term must be calculated from the earliest effective nonprovisional priority or filing date, subject to patent-term adjustment, patent-term extension and terminal disclaimers. The grant date, February 28, 2012, does not by itself determine expiration.

Public patent records identify US 8,124,630 as a later sorafenib method-of-use patent in the Nexavar estate. The relevant expiration analysis should distinguish it from earlier sorafenib compound patents and from later formulation or indication patents.

Exclusivity category	Relevance to sorafenib
FDA new chemical entity exclusivity	Applied to the initial Nexavar approval and expired years before current generic competition
Compound patent protection	Protects sorafenib as a chemical entity and may have expired before the method patents
Method-of-use protection	The principal protection supplied by US 8,124,630
Formulation protection	Not supplied by the claims quoted
Pediatric extension	Applies only if granted for the specific qualifying product and patent
Patent-term extension	Must be confirmed from USPTO and FDA records for each patent

The Orange Book should be checked for the patent number, use code, expiration date and any pediatric extension associated with Nexavar.[2] A patent’s presence in the Orange Book does not establish validity. It does, however, affect ANDA certification and the timing of FDA approval.

What is the Orange Book status of Nexavar and sorafenib?

Nexavar is an FDA-approved prescription drug. The FDA Orange Book lists patents and use codes supplied by the NDA holder for approved products.[2] For a method-of-use patent, an ANDA applicant can generally seek approval through a section viii statement that omits the patented use, provided the proposed labeling does not include that use. A Paragraph IV certification is used when the applicant asserts that a listed patent is invalid, unenforceable or will not be infringed.

The commercial importance of US 8,124,630 depends on the use code submitted for the patent. If the use code corresponds to an indication included in a generic label, the patent may create Paragraph IV litigation exposure. If the indication is carved out, the patent may have limited practical effect unless the generic is marketed or prescribed for the patented use.

What Paragraph IV challenges and litigation affect sorafenib?

Sorafenib has faced the normal generic-entry pathway for a small-molecule oncology product. ANDA applicants may challenge compound, method-of-use and formulation patents through Paragraph IV certifications. Litigation risk depends on the exact patent list in effect on the ANDA filing date and the proposed product label.

The key litigation questions are:

Whether US 8,124,630 was listed for the relevant Nexavar indication.
Whether the ANDA label included a patented use.
Whether the applicant used a section viii carve-out.
Whether Bayer or another patent owner filed suit within the statutory 45-day period.
Whether the case ended in judgment, dismissal or settlement.
Whether any settlement restricted launch before the relevant patent expiration.

The quoted claims are method claims. They do not automatically block every sorafenib tablet. A generic product that is approved only for unpatented uses may avoid infringement through a properly drafted label. The analysis changes if the generic label includes lung, pancreatic, bladder or colon carcinoma, myeloid leukemia or villous colon adenoma treatment.

How strong is the patent estate for sorafenib?

The estate is strongest when viewed as a layered portfolio rather than through US 8,124,630 alone.

Protection layer	Strategic value
Original compound patent	Broadest chemical protection, but generally earliest to expire
Method-of-treatment patents	Can delay approval or restrict labeling for specified diseases
Salt claims	Support protection for sorafenib tosylate, the marketed form
Formulation patents	Can cover tablet composition, release or stability features
Manufacturing patents	Can raise production costs or complicate independent API supply
Regulatory exclusivity	Applies separately from patent rights and usually expires earlier
Pediatric extension	Can extend selected patent terms where statutory requirements are met

US 8,124,630 is narrower than a compound patent but potentially more relevant to generic labeling. Its strength is highest for a product label that expressly instructs treatment of one of the named cancers or myeloid leukemia with sorafenib tosylate.

Its weaknesses include the absence of dosing and formulation limitations, potential written-description and enablement questions for the full disease list, and the naming inconsistency between “2-carbamoyl” and “N-methylcarbamoyl.” The practical effect of those weaknesses depends on the prosecution history and prior art.

What formulation patents protect Nexavar?

The claims supplied do not protect a tablet formulation. They protect administration of the active compound or tosylate salt for specified diseases.

Separate patent families may address:

Sorafenib tosylate compositions.
Oral tablets.
Excipients and stability.
Particle size or solid-state properties.
Manufacturing and crystallization.
Combination regimens.
Later indications.

A generic manufacturer can avoid a formulation patent by using a noninfringing excipient system or manufacturing process. It may have less flexibility against a method patent if the proposed label expressly includes the patented use.

Does biosimilar risk apply to sorafenib?

No. Sorafenib is a chemically synthesized small molecule, not a biologic. The relevant competitors are ANDA-based generic manufacturers, not biosimilar applicants under the Biologics Price Competition and Innovation Act.

Potential competitors include companies that file abbreviated new drug applications for sorafenib tablets or sorafenib tosylate tablets. Their exposure depends on the Orange Book patent list, proposed indications and certification strategy.

Which companies may challenge the Nexavar patent estate?

The likely challenger group consists of generic drug companies with oncology tablet capabilities, including large U.S., Indian and European ANDA sponsors. Publicly meaningful status must be determined from FDA approval records, Orange Book certifications and federal docket filings rather than from the existence of a patent application alone.

Relevant competitive categories include:

Authorized or affiliated generic suppliers.
Independent ANDA filers.
API manufacturers with sorafenib tosylate capacity.
Regional generic companies seeking approval outside the United States.
Specialty oncology companies pursuing label-specific launches.

A company can enter with a narrow label even when a broader Nexavar patent remains listed. This makes label design, not only patent validity, central to market timing.

What generic launch scenarios exist?

Scenario 1: Full-label generic launch

A generic applicant challenges relevant patents through Paragraph IV certification and seeks approval for all commercially important Nexavar indications. This produces the highest litigation exposure but gives the broadest market access.

Scenario 2: Section viii carve-out

The applicant removes patented indications from its label. This can permit approval without challenging every method patent. The approach may reduce market share and create risk if promotional activity or product distribution encourages use for the carved-out indications.

Scenario 3: Authorized generic or negotiated entry

The originator or an affiliate supplies a generic version, or the parties settle litigation with an agreed launch date. Such an arrangement can preserve value for the patent holder while allowing a controlled transition.

Scenario 4: Post-expiration launch

The generic waits for the relevant patent term to expire. This reduces litigation cost but sacrifices first-mover timing and may allow multiple competitors to enter simultaneously.

What geographic coverage does the patent provide?

US 8,124,630 provides rights only in the United States. It does not directly block use, manufacture or sale in Europe, Japan, China, Canada or other jurisdictions.

International protection depends on corresponding national patents and their legal status. The relevant comparison should include:

Jurisdiction	Required review
United States	USPTO term, Orange Book listing, ANDA certifications and litigation
European Union	National validations, SPC status and country-specific litigation
Japan	Patent term and PMDA product status
China	CN family member, invalidation history and regulatory approval
Canada	Patent Register listing and PM(NOC) proceedings
India	National patent scope and generic launch status

A U.S. method patent cannot prevent an overseas manufacturer from selling a non-U.S. product, although export, supply-chain and regulatory conduct may create separate legal issues.

What manufacturing and intellectual-property barriers remain?

Sorafenib tosylate production is technically manageable for experienced generic manufacturers, but commercial entry requires:

A reliable sorafenib API source.
Control of salt formation and solid-state properties.
Consistent tablet dissolution.
Bioequivalence to the reference product.
Compliance with FDA chemistry, manufacturing and controls requirements.
A noninfringing formulation and process.
A legally compliant label.

US 8,124,630 does not claim the manufacturing method. A manufacturer could therefore avoid this patent by producing sorafenib tosylate for an unpatented indication or by using a different process, subject to other patents in the family.

How does US 8,124,630 compare with a sorafenib compound patent?

Issue	US 8,124,630	Compound patent
Claim type	Method of treatment	Chemical compound or composition
Scope	Selected diseases	Potentially all uses of sorafenib
Product blocked	Product used for claimed indication	Sorafenib product generally
Label relevance	Very high	High
Design-around potential	Label carve-out or use restriction	Low before expiration
Regulatory mechanism	Paragraph IV or section viii	Primarily Paragraph IV
Commercial leverage	Indication-specific	Product-wide

The compound patent is generally the stronger barrier while active. US 8,124,630 can retain value after compound protection weakens if its covered indications remain commercially important and cannot be carved out without materially reducing market access.

Key Takeaways

US 8,124,630 is a sorafenib method-of-treatment patent, not a compound or tablet patent.
The claims cover lung, pancreatic, thyroid, bladder and colon carcinomas, myeloid leukemia and villous colon adenoma.
Claims 8 through 14 specifically cover sorafenib tosylate, the active pharmaceutical form used in Nexavar.
The patent contains no dose, formulation, biomarker or combination-treatment limitation.
The main generic-entry issue is whether a proposed ANDA label includes a patented indication or can use a section viii carve-out.
Sorafenib is a small molecule, so biosimilar law is not relevant. ANDA and Paragraph IV procedures control U.S. generic entry.
The exact expiration date must be taken from the USPTO patent-term record and reconciled with any terminal disclaimer, patent-term adjustment, pediatric extension and Orange Book data.
The patent provides U.S. rights only. Foreign market protection requires separate national family members.
The claim-name inconsistency between “2-carbamoyl” and “N-methylcarbamoyl” is a potential claim-construction issue, while the disclosed formula identifies the intended compound as sorafenib.

FAQs About US Patent 8,124,630

Is US 8,124,630 a patent on Nexavar itself?

No. It is a method-of-treatment patent. Sorafenib compound protection resides in separate patent families.

Does a sorafenib generic automatically infringe this patent?

No. Infringement depends on the use promoted, instructed or otherwise covered by the generic label and on the specific claim construction.

Can a generic obtain FDA approval by removing patented indications?

Yes. An ANDA applicant may use a section viii statement to carve out a patented method of use if the resulting label remains adequate for the unpatented indications.

Does the patent cover sorafenib combinations?

Not expressly. The supplied claims require administering sorafenib or sorafenib tosylate but do not recite a second active ingredient or combination regimen.

Does the patent cover treatment of renal cell carcinoma or hepatocellular carcinoma?

Not based on the claims supplied. The listed carcinoma claims identify lung, pancreas, thyroid, bladder and colon. Other patents or regulatory exclusivities may address renal cell carcinoma or hepatocellular carcinoma.

References

U.S. Food and Drug Administration. (2005). Nexavar (sorafenib tosylate) prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
United States Patent and Trademark Office. (2012). U.S. Patent No. 8,124,630, treatment methods involving sorafenib. USPTO.
U.S. Food and Drug Administration. (1984). Drug Price Competition and Patent Term Restoration Act. FDA.
Bayer AG. (Various years). Annual reports and pharmaceutical product disclosures concerning Nexavar. Bayer AG.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1140840	⤷ Start Trial	91280	Luxembourg	⤷ Start Trial
European Patent Office	1140840	⤷ Start Trial	PA2006008	Lithuania	⤷ Start Trial
European Patent Office	1140840	⤷ Start Trial	300242	Netherlands	⤷ Start Trial
European Patent Office	1140840	⤷ Start Trial	06C0034	France	⤷ Start Trial
European Patent Office	1140840	⤷ Start Trial	CA 2007 00002	Denmark	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,124,630

Summary for Patent: 8,124,630